Clinical Trials Details

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (Hoffmann-LaRoche GO42784)

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician’s choice (TPC: eltrozole, anastrozole, exemestane, or tamoxifen) in participants with medium- and highrisk Stage I-III histologically confirmed ER+ and HER2- EBC. Participants will be treated with giredestrant or TPC for at least 5 years. During the study, participants will be regularly assessed for efficacy, safety, and HRQoL. After completing the study treatment phase, participants will enter long-term follow-up for at least 5 years.

Learn More

Principal Investigator(s)

Steve Lo, MD


Mary Miller, LPN at 203-358-8879 or [email protected]


Bennett Cancer Center
One Hospital Plaza
Stamford, CT 06902
Main: 203-276-2695

Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.